This study is testing AP-472, an oral tablet, to see if it can help people with Parkinson's disease who experience "motor fluctuations" (times when their Parkinson's symptoms change, even while taking levodopa). Researchers want to find out how effective two different doses of AP-472 are when added to your current levodopa treatment, compared to a placebo (an inactive tablet that looks like the study drug). You could be eligible if you are between 30 and 80 years old, have a Parkinson's diagnosis, and experience these motor fluctuations. The main goal is to see if AP-472 reduces the amount of time you experience "OFF" periods (when Parkinson's symptoms are not well controlled) over 12 weeks. The current recruitment status is unclear, and 150 participants are planned.

Study design

This is a Phase 2, interventional study. You would be randomly assigned to receive one of two doses of AP-472 or a placebo, and neither you nor the study staff would know which treatment you are receiving. The study plans to enroll 150 participants.

What's involved

The study lasts about 12 weeks, including a screening period, a 4-week period where your Parkinson's medications must remain stable, and an 8-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at Week 12, which suggests the main observation period for effectiveness ends around that time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.